Summary Oral administration of insulin suppresses the development of diabetes in nonobese diabetic (NOD) mice and deviates the cytokine balance in the islets of Langerhans from a Th1 to a Th2 type cytokine pattern. However, the effect of oral insulin is limited and disease suppression is limited to a narrow dose range. Therefore we tried to improve the outcome of suboptimal insulin dosing by bacterial adjuvant. Mice treated with a suboptimal dose of oral insulin showed no change in diabetes incidence although a shift from Th1 towards Th2 cytokine expression occurred in inflamed islets. Significant suppression of diabetes development was only seen in NOD mice receiving both, insulin and the bacterial preparation OM-89 as adjuvant. OM-89 is a protein extract of Escherichia coli, with nonspecific immunostimulatory properties. Potentiation of the effect of oral insulin by the adjuvant was associated with upregulation of interleukin (IL)-4 Th2 cells in infiltrated islets and sustained local IL-2 gene expression. RT PCR analyses of cytokine expression in the gut showed a clear deviation to Th2 type reactivity and downregulation of inducible nitric oxide (NO) synthase (iNOS) expression by the bacterial adjuvant but not by oral insulin alone. Since macrophages are the primary target cells of adjuvant action we tested its effect on mouse macrophages in vitro. Treatment with OM-89 induced transient release of tumour necrosis factor alpha and nitrite but rendered macrophages refractory to restimulation by the potent macrophage activator lipopolysaccharide. In conclusion, the protective effect of oral insulin can be potentiated by pretreatment with the bacterial adjuvant OM-89. This effect correlates with enhanced Th2 cytokine and decreased iNOS gene expression in the gut, probably due to the downregulation of proinflammatory mediators by exposure to the adjuvant. [Diabetologia (1997) 40: 902-909] Keywords Diabetes mellitus, oral tolerance, mucosal immunology, antigen presenting cells, Th2 cytokines.
Attempts to intervene in the disease process therefore have focussed on supporting "protective" Th2 over "diabetogenic" Th1 reactivities by antigen specific or non-specific treatment modalities [5] [6] [7] [8] . Because of an apparently low risk of adverse effects, a promising approach of Th1/Th2 immune deviation is the mucosal administration of antigen. Peroral administration of target autoantigens has been shown to mitigate or suppress Th1 dependent autoimmune diseases such as experimental autoimmune encephalomyelitis or collagen induced rheumatoid arthritis in rodents [9] [10] [11] . Dependent on the antigen dose administered there is a deletion or anergy of specific T cells, or an induction of Th2-type antigen reactive T cells. The latter cells are thought to migrate to the respective target organ, become activated upon re-encounter of antigen and exert bystander suppression of any local Th1 dependent inflammation through their release of interleukin (IL)-4, IL-10, transforming growth factor beta (TGFb) or other Th2 type mediators [12, 13] . Deviation from cellular to humoral immunity after oral pretreatment with antigen has also been observed in humans [14] .
Indeed, recent studies indicate that oral administration of insulin affects the development of diabetes in NOD mice through the generation of cells that suppress the progression of insulitis [15, 16] . This probably occurs through the release of cytokines within the target organ which shift the balance from a Th1 to a Th2 pattern of cytokine expression [17] . However, the effects of such treatment were limited in that oral insulin only partially reduced the diabetes incidence in NOD mice. Moreover, the therapeutic dose range of oral insulin was very narrow [15] . It therefore seems desirable to potentiate the protective effects of oral insulin in NOD mice.
A previous study in an animal model of experimental autoimmune encephalomyelitis reported that the use of lipopolysaccharide (LPS) as adjuvant improved the outcome of oral antigen treatment [18] . Since oral endotoxin treatment may not be devoid of adverse effects, including the induction of autoantibody formation in the peritoneal cavity and lamina propria [19] we selected an LPS-free bacterial preparation as adjuvant. OM-89 is a protein extract of Escherichia coli containing mainly acidic glycoproteins of 10-300 kDa molecular weight and less than 12 ppm LPS [20] [21] [22] . This compound is presently being used for adjuvant treatment of some infectious diseases and rheumatoid arthritis [20, 23] . We also studied the mechanism of adjuvant action by determining cytokine production in vivo and in vitro.
Materials and methods
Animals. Female NOD mice (nonobese diabetic, NOD/Bom) were purchased at Bomholtgard Breeding Centre (Ry, Denmark) and were kept under conventional conditions with standard diet for mice (Ssniff, Soest, Germany) with tap water ad libitum. "Principles of animal care" as well as the German Law on the Protection of Animals were followed.
Experimental design. The NOD mice were allocated at random to four different treatment groups. Each group consisted of 36 animals. Mice were treated orally on 3 consecutive days per week for 5 weeks; starting at 7 weeks of age. Thereafter the treatment was reduced to 2 days of treatment every second week and stopped on day 140. The CTL group comprised sham treated animals receiving 0.9 % NaCl orally. The INS group was fed 0.9 % NaCl, and the last treatment each week was 1 mg of porcine insulin (kind gift of Hoechst, Frankfurt, Germany). The OM group received 200 mg/kg body weight of OM-89 (kind gift of Laboratoire OM, Geneva, Switzerland) and the last treatment each week was saline. Mice of the OM + INS group received OM-89 and the last treatment each week was insulin.
Animals were monitored for glucosuria twice a week (Diabur; Boehringer Mannheim, Mannheim, Germany). Diabetes was confirmed after 3 consecutive days of glucosuria by hyperglycaemia (L 14 mmol/l), as determined in blood samples from non-fasted animals by the hexokinase method.
Histological analyses. On day 162 five non-diabetic animals per group were killed pancreas and gut were snap frozen in liquid nitrogen prechilled isopentane and stored at -80°C. Histological analysis and immunohistochemistry were done on acetonefixed cryostat sections. Sections for histology were stained with haematoxylin and eosin and were evaluated for mononuclear infiltration using the following semiquantitative rating system: score 0, no periductular infiltrates and less than 5 immune cells peri-and intrainsular; score 1, periductular infiltrates only; score 2: periductular and peri-insular infiltrates only; score 3, intraislet infiltration of less than 20 % of the islet area; score 4, intraislet infiltration of more than 20 % of the islet area. Buffers for cytokine-staining [3] were supplemented with 0.05 % saponine (Sigma, Deisenhofen, Germany). Monoclonal antibodies against murine IL-4 and Il-2 were obtained from Pharmingen (clone BVD6-24G2 and clone S4B6; San Diego, Calif, USA). The total number of mononuclear cells surrounding and infiltrating islets was counted and the percentage of cytokine positive mononuclear cells per islet was determined. In each series of sections control stainings without first or second antibody were performed in order to check for background staining. In addition irrelevant rat monoclonal antibodies were used as negative controls. mRNA analysis. Total RNA was isolated from whole small bowel by Trizol Reagent (Gibco BRL, Berlin, Germany). Determination and quantification of specific mRNA was performed by reverse transcriptase polymerase chain reaction (RT-PCR) as described elsewhere [3, 24] . Control experiments to check for linear relationship between amount of PCR product and amplification cycle number were performed. Specific primers were used for b -actin, interferon gamma (IFNg), IL-10, TGFb (Clontech Laboratories Inc., Palo Alto, Calif., USA) and inducible nitric oxide synthase (iNOS) [25] . PCR products were labelled by hybridization to 32 P labelled probes binding at sides between the primer sequences. Signals were quantified by measuring the 32 P stimulated luminescence (PSL) by a phosphoimager. Relative PSL was calculated by normalization of the measured PSL to the strength of the b -actin signal [3] .
Macrophage culture. The murine macrophage cell line IC21 was provided by ATCC (Rockville, Md., USA). Cells were cultured in petri dishes at 1 × 10 medium (Gibco, Heidelberg, Germany) supplemented with 10 % (v/v) fetal calf serum (FCS; Gibco) and 2 mmol/l l -glutamine. Cells were precultured for 24 h with OM-89 or sham treated with culture medium. After 24 h cells were washed with prewarmed RPMI 1640 and stimulated with LPS (E. coli 026:B6; Sigma, Deisenhofen, Germany), OM-89 or were sham treated. After 48 h supernatants were collected and nitrite and tumour necrosis factor alpha (TNFa) levels were determined by Griess method [26] or TNFa-bioassay [27] , respectively, as described previously.
Statistical analysis
Diabetes incidence between groups was compared by the method of Kaplan and Meier. Immunohistochemistry data and RT-PCR analysis were compared by the Mann-Whitney-U test. Cell culture experiment data were derived from three different experiments. Mean values were calculated and are presented with their standard deviation. Mean values were compared by two tailed Student's t-test. The level of significance was set at p less than 0.05.
Results
Synergistic effect of oral insulin and OM-89 on diabetes prevention. NOD mice were treated orally with 0.9 % NaCl, insulin (1 mg), OM-89 (200 mg/kg body weight) or OM-89 and insulin as described. Diabetes incidence (Fig. 1 a) was significantly reduced in the group receiving OM-89 and insulin compared to the control group (p < 0.05). The insulin treated group showed a slightly delayed onset of diabetes, but reached the control level of diabetes incidence by the end of the experiment. Body weight did not differ significantly in all groups (Fig. 1 b) .
Histological analysis. Semiquantitative analysis of insulitis was performed on day 162. This date was chosen in order to determine insulitis quality at peak disease activity. In the control group 66 % of islets showed advanced stages of islet inflammation (scores 3-4). Treatment with OM-89 did not alter the histological picture, while the INS and OM + INS group showed a major decrease of severe insulitis (Fig. 2) .
Impact on cytokine expression in islets.
Pancreas sections were analysed by immunohistochemistry for the Th2 type cytokine IL-4 and the Th1 type cytokine IL-2 in the islet infiltrate. In saline treated NOD mice less than 10 % of infiltrating mononuclear cells were positive for IL-4 while 26 % of cells expressed IL-2 (Fig. 3) . Only islets with insulitis scores 3-4 ( Fig. 2) were analysed, shown are mean scores of analysed islets. Statistical analysis was performed between indicated bars and control group macrophages became refractory towards restimulation with the potent macrophage activator LPS. This was observed for both inflammatory macrophage products, TNFa and nitrite (Fig. 5 ).
Discussion
Recent reports have shown a decrease in diabetes incidence in mice by approximately 50 % after feeding a dose of 1 mg porcine insulin [15] . In our study we used the same dose of insulin, but our protocol foresaw only one application of insulin per week, so that the total dosage of insulin applied over a period of 15 weeks was 50 % smaller than previously [15] . This suboptimal protocol of oral insulin therapy was chosen in order to recognize better any potentiating effects of the bacterial preparation OM-89. Indeed, treatment of prediabetic NOD mice with oral insulin alone did not significantly suppress diabetes incidence although a transient small delay was observed. In contrast, mice that received the bacterial adjuvant prior to insulin showed a major delay in diabetes development and significant suppression of overt diabetes at any point of time beyond 157 days of age. This preventive effect was due to a synergistic effect of insulin and the adjuvant since oral administration of OM-89 alone did not alter the course of the disease.
Our results suggest that combination of oral antigen with a bacterial adjuvant can reduce the dosage of antigen without losing the therapeutic effect. This indicates that bacterial adjuvants can shift the therapeutic antigen dosage towards smaller amounts of antigen. Semiquantitative analysis of insulitis confirmed that the administration of OM-89 alone had not affected disease progression while there was a significant decrease of islets with intrainsulitis in mice receiving OM-89 plus insulin. Surprisingly, intrainsular infiltration was similarly reduced in the group receiving insulin alone. This may reflect the delay of diabetes development seen at the time of insulitis analyses (day 162).
A major difference between insulin and adjuvant plus insulin groups became apparent when staining cytokine expression within affected islets. We chose the two cytokines IL-2 and IL-4 as indicators of Th1 or Th2 reactivity, since these gave the strongest signal for either type of immunoreactivity in islets of NOD mice with spontaneous development of diabetes while in cyclophosphamide accelerated diabetes development IFNg is the predominant Th1 cytokine [3] . Insulitis in sham treated control mice was characterized by a clear dominance of IL-2 positive over IL-4 positive cells, indicating a bias towards Th1 type reactivity. Treatment with oral insulin alone completely reversed the immunoregulatory balance, leading to a dramatic increase of IL-4 positive infiltrate while IL-2 positive cells were barely detectable. These changes correspond to those described by Hancock et al. [17] for the more intense oral insulin dosing protocol.
Upregulation of IL-4 positive cells in the infiltrate was also seen in the group receiving adjuvant plus insulin. However, there was no decrease in the percentage of IL-2 positive cells. Since the combined treatment with the bacterial preparation and insulin suppressed the progression towards diabetes, it is conceivable that the release of IL-2 in conjunction with IL-4 is superior in limiting destructive insulitis than IL-4 alone. One major protective effect of IL-2 in the presence of IL-4 may be its growth promoting, anti-apoptotic effect. Indeed, Zhang et al. [28] recently showed proliferation of Th2 effector cells and prevention of apoptotic cell death in the presence of IL-2 while prolonged, dramatic expansion of Th1 cells occurred during IL-2 deficiency. Impaired IL-2 production has been reported to be a characteristic of IDDM and its animal models [29] [30] [31] [32] . A protective effect of IL-2 injections was reported in a BB rat line with high diabetes risk [33] and transgenic mice expressing IL-2 under the rat insulin promotor developed apparently benign insulitis because progression to diabetes was rarely observed [34] . We conclude that IL-2 may not only function as a Th1 cytokine but may also sustain ongoing Th2 responses in the presence of IL-4.
The different cytokine pattern induced by insulin or by insulin plus adjuvant indicates some variability in the outcome of oral tolerization. Hence, it is not surprising that oral antigen dosing was recently even found in settings particularly to exacerbate autoimmune disease [35, 36] .
In order to understand how the adjuvant might have affected the gut mucosa immune response to oral insulin we analysed the cytokine expression pattern in the gut. Because IL-10 and TGFb are the major anti-inflammatory Th2 type cytokines, but not IL-4 [3] , the former two were analysed, in parallel with IFNg as a key Th1 cytokine in the gut. As marker of macrophage and/or epithelial cell activation iNOS mRNA was determined. The normal NOD gut showed little IFNg and a predominance of IL-10 and TGFb mRNA. Interestingly, substantial amounts of iNOS mRNA were found. IL-10 gene expression was increased by treatment with OM-89 while insulin alone failed to induce IL-10. Similarly, TGFb, a cytokine typical for tolerance induction [24, 37, 38] , was elevated by OM-89 but not by insulin administration. Conversely, iNOS mRNA was decreased by OM-89 treatment while oral insulin alone did not downregulate iNOS gene expression. Interestingly, IFNg was slightly elevated in the gut of the insulin treated group.
In summary, the cytokine profile of the gut shows a clear deviation of the immune balance to Th2 type reactivity by oral treatment with bacterial adjuvant OM-89 but not by oral application of insulin alone. It is known that the cytokine milieu present during antigen presentation is crucial in driving T cell responses compared to Th1 or Th2. In the presence of IL-10 and TGFb, responses to oral insulin will be biased towards Th2. Potentiation of the apparent Th2 bias of the gut by OM-89 can be expected to drive Tcell responses even more strongly towards Th2. This view is in accord with the observed synergism of OM-89 and suboptimal insulin dosage. It remains to be determined whether the disease suppressing effects of optimal oral antigen doses can be further enhanced by adjuvant.
What is the target of adjuvant action? It has been reported that the immunostimulatory peptides of OM-89 interact with macrophages rather than with T cells [39] . Hence, mucosal antigen presenting cells are probably the major targets of OM-89 in the gut. A change in the functional state of antigen presenting cells in the gut might affect the outcome of antigen presentation. Bacterial immunostimulatory compounds such as OM-89 are known to induce the release of proinflammatory Th1 type mediators in macrophages [40] or other antigen presenting cells [41] . However, as we show here, exposure to the bacterial adjuvant prevented restimulation and further release of proinflammatory mediators. This desensitizing action of OM-89 seen in vitro is reminiscent of the phenomenon of LPS tolerance [42] and fits well with the suppression of iNOS mRNA observed here in the gut of OM-89 treated NOD mice.
We conclude that the protective effect of oral insulin on the progression of insulitis and the development of overt diabetes in NOD mice can be potentiated by pretreatment with the bacterial adjuvant OM-89. This effect correlates with enhanced Th2 cytokine and decreased iNOS gene expression, probably as a consequence of local downregulation of proinflammatory Th1 type mediators by repeated exposure to the adjuvant.
